Photodynamic therapy induced enhancement of tumor vasculature permeability using an upconversion nanoconstruct for improved intratumoral nanoparticle delivery in deep tissues

Theranostics

Volumn 6, Issue 8, 2016, Pages 1131-1144

  Gao, Weidong ^a   Wang, Zhaohui ^a   Lv, Liwei ^a   Yin, Deyan ^a   Chen, Dan ^a   Han, Zhihao ^a   Ma, Yi ^a   Zhang, Min ^a   Yang, Man ^a   Gu, Yueqing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Drug delivery; EPR; Nanoparticles; Photodynamic therapy; Upconversion

Indexed keywords

DOXORUBICIN; GOLD NANOPARTICLE; LIPOSOME; UPCONVERSION NANOPARTICLE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; NANOPARTICLE;

ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CHEMICAL ANALYSIS; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IRRADIATION; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; PROCESS OPTIMIZATION; PROSTATE CANCER; PROTEIN MODIFICATION; TOXICITY TESTING; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME; VALIDATION STUDY; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD VESSEL; DISEASE MODEL; DRUG EFFECTS; MALE; NUDE MOUSE; PERMEABILITY; PHOTOCHEMOTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD VESSELS; DISEASE MODELS, ANIMAL; DOXORUBICIN; HETEROGRAFTS; MALE; MICE, NUDE; NANOPARTICLES; PERMEABILITY; PHOTOCHEMOTHERAPY; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84984706717     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.15262     Document Type: Article

References (35)

1. Mitragotri S, Anderson DG, Chen X, Chow EK, Ho D, Kabanov AV, et al. Accelerating the Translation of Nanomaterials in Biomedicine. ACS nano. 2015; 9: 6644-54.
2. Jin L, Zeng X, Liu M, Deng Y, He N. Current progress in gene delivery technology based on chemical methods and nano-carriers. Theranostics. 2014; 4: 240-55.
3. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine: NBM. 2013; 9: 1-14.
4. Zhang F, Zhu L, Liu G, Hida N, Lu G, Eden HS, et al. Multimodality imaging of tumor response to doxil. Theranostics. 2011; 1: 302-9.
5. Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics -application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014; 4: 660-77.
6. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvascular research. 1986; 31: 288-305.
7. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer research. 1986; 46: 6387-92.
8. Kobayashi H, Watanabe R, Choyke PL. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics. 2013; 4: 81-9.
9. Park K. Facing the truth about nanotechnology in drug delivery. ACS nano. 2013; 7: 7442-7.
10. Maeda H, Matsumura Y. EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy. Advanced drug delivery reviews. 2011; 63: 129-30.
11. Durymanov MO, Rosenkranz AA, Sobolev AS. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines. Theranostics. 2015; 5: 1007-20.
12. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Advanced drug delivery reviews. 2013; 65: 71-9.
13. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer research. 2003; 63: 8126-31.
14. Zhen Z, Tang W, Chuang YJ, Todd T, Zhang W, Lin X, et al. Tumor vasculature targeted photodynamic therapy for enhanced delivery of nanoparticles. ACS nano. 2014; 8: 6004-13.
15. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA: a cancer journal for clinicians. 2011; 61: 250-81.
16. Luo D, Carter KA, Razi A, Geng J, Shao S, Lin C, et al. Porphyrin-phospholipid liposomes with tunable leakiness. Journal of controlled release: official journal of the Controlled Release Society. 2015; 220: 484-94.
17. Cui S, Yin D, Chen Y, Di Y, Chen H, Ma Y, et al. In vivo targeted deep-tissue photodynamic therapy based on near-infrared light triggered upconversion nanoconstruct. ACS nano. 2013; 7: 676-88.
18. Cui SS, Chen HY, Zhu HY, Tian JM, Chi XM, Qian ZY, et al. Amphiphilic chitosan modified upconversion nanoparticles for in vivo photodynamic therapy induced by near-infrared light. J Mater Chem. 2012; 22: 4861-73.
19. Wang C, Cheng L, Liu Z. Upconversion nanoparticles for photodynamic therapy and other cancer therapeutics. Theranostics. 2013; 3: 317-30.
20. Luk BT, Fang RH, Zhang L. Lipid-and polymer-based nanostructures for cancer theranostics. Theranostics. 2012; 2: 1117-26.
21. Zhang Y, Yang Y, Cai W. Multimodality Imaging of Integrin alpha(v)beta(3) Expression. Theranostics. 2011; 1: 135-48.
22. Chen K, Chen X. Integrin targeted delivery of chemotherapeutics. Theranostics. 2011; 1: 189-200.
23. Melemenidis S, Jefferson A, Ruparelia N, Akhtar AM, Xie J, Allen D, et al. Molecular magnetic resonance imaging of angiogenesis in vivo using polyvalent cyclic RGD-iron oxide microparticle conjugates. Theranostics. 2015; 5: 515-29.
24. Ricci-Junior E, Marchetti JM. Zinc(II) phthalocyanine loaded PLGA nanoparticles for photodynamic therapy use. International journal of pharmaceutics. 2006; 310: 187-95.
25. Xing Y, Zhao J, Conti PS, Chen K. Radiolabeled nanoparticles for multimodality tumor imaging. Theranostics. 2014; 4: 290-306.
26. Kim BK, Seu YB, Choi JS, Park JW, Doh KO. Synthesis and validation of novel cholesterol-based fluorescent lipids designed to observe the cellular trafficking of cationic liposomes. Bioorganic & medicinal chemistry letters. 2015; 25: 3893-6.
27. Xue J, Shan L, Chen H, Li Y, Zhu H, Deng D, et al. Visual detection of STAT5B gene expression in living cell using the hairpin DNA modified gold nanoparticle beacon. Biosensors & bioelectronics. 2013; 41: 71-7.
28. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer research. 2000; 60: 6950-7.
29. Li Z, Zhang Y. An efficient and user-friendly method for the synthesis of hexagonal-phase NaYF(4):Yb, Er/Tm nanocrystals with controllable shape and upconversion fluorescence. Nanotechnology. 2008; 19: 345606.
30. Trynda-Lemiesz L. Paclitaxel-HSA interaction. Binding sites on HSA molecule. Bioorganic & medicinal chemistry. 2004; 12: 3269-75.
31. Li R, Zheng K, Hu P, Chen Z, Zhou S, Chen J, et al. A novel tumor targeting drug carrier for optical imaging and therapy. Theranostics. 2014; 4: 642-59.
32. Chen H, Zhang X, Dai S, Ma Y, Cui S, Achilefu S, et al. Multifunctional gold nanostar conjugates for tumor imaging and combined photothermal and chemo-therapy. Theranostics. 2013; 3: 633-49.
33. Hong CA, Nam YS. Functional nanostructures for effective delivery of small interfering RNA therapeutics. Theranostics. 2014; 4: 1211-32.
34. Bhuvaneswari R, Gan YY, Soo KC, Olivo M. The effect of photodynamic therapy on tumor angiogenesis. Cellular and molecular life sciences: CMLS. 2009; 66: 2275-83.
35. Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. The Journal of clinical investigation. 2014; 124: 617-30.